China to cut prices of expensive patent drugs
BEIJING, May 20 (Xinhua) -- China's health authority on Friday announced cuts of over 50 percent in the prices of three patent drugs.
The National Health and Family Planning Commission said through pharmaceutical manufacturers have agreed to lower some drugs' prices on condition of bulk purchase.
GlaxoSmithCline (GSK) will reduce the price of Tenofovir Disoprox, a treatment for hepatitis B, from 1500 yuan (229 U.S.dollars) to 490 yuan per month.
Icotinib, an anti-cancer drug made by China's Betta Pharmaceuticals, will be dropped from 12,000 yuan to 5,500 yuan for a month's supply.
AstraZeneca will lower the monthly cost for the anti-cancer Gefitinib from 15,000 yuan to 7,000 yuan.
High prices of imported and patent drugs are a great burden for Chinese patients and the country as a whole.
- China Medical Expert Team arrives in DR Congo to aid battle against Ebola, leveraging expertise and China's experience in epidemic control: team members
- China to send medical expert team to DR Congo for Ebola control
- Senior WHO official highlights China's role in tackling global health challenges
- Focus on the World Health Assembly | Healthy China, not just China
- China builds robust nursing workforce amid healthcare push
- NHC minister meets with president of Merieux Foundation